Corbus Pharmaceuticals (NASDAQ:CRBP) Director Sells $15,680.00 in Stock

Posted by Geri Gentry on Sep 18th, 2026

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) Director Yong Ben sold 2,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $7.84, for a total transaction of $15,680.00. Following the completion of the transaction, the director directly owned 9,383 shares in the company, valued at approximately $73,562.72. The trade was a 17.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Corbus Pharmaceuticals Stock Performance

Shares of CRBP opened at $7.26 on Friday. The stock has a 50 day moving average price of $9.61 and a two-hundred day moving average price of $9.42. The firm has a market capitalization of $135.54 million, a P/E ratio of -1.17 and a beta of 2.63. Corbus Pharmaceuticals Holdings, Inc. has a 52 week low of $6.32 and a 52 week high of $20.56.

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.55). On average, equities analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -5.62 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Guggenheim reiterated a “buy” rating on shares of Corbus Pharmaceuticals in a report on Tuesday, May 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Corbus Pharmaceuticals in a research note on Monday. Oppenheimer reduced their target price on Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating for the company in a report on Friday, August 7th. Finally, Mizuho set a $33.00 price target on Corbus Pharmaceuticals in a research report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Check Out Our Latest Stock Report on Corbus Pharmaceuticals

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Orbimed Advisors LLC grew its stake in Corbus Pharmaceuticals by 8.8% during the first quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock valued at $16,313,000 after acquiring an additional 140,000 shares in the last quarter. Exome Asset Management LLC boosted its holdings in Corbus Pharmaceuticals by 67.8% in the 1st quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock valued at $2,199,000 after purchasing an additional 94,593 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Corbus Pharmaceuticals by 76.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company’s stock valued at $1,281,000 after purchasing an additional 59,248 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Corbus Pharmaceuticals during the 4th quarter valued at $462,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Corbus Pharmaceuticals in the second quarter worth $425,000. 64.64% of the stock is owned by institutional investors.

Corbus Pharmaceuticals Company Profile

(Get Free Report)

Corbus Pharmaceuticals Holdings, Inc is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research programs are designed to target biological pathways involved in tumor growth, immune regulation and tissue fibrosis.

Corbus’s oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, a protein expressed on several solid tumors. The company is also developing CRB-601, an investigational monoclonal antibody directed at the alpha v beta 6 integrin, a target associated with tumor biology and fibrotic disease.